Literature DB >> 11898510

Treatment of childhood headaches.

A Gupta1, A D Rothner.   

Abstract

Migraine and tension-type headaches are two of the most common types of primary headache disorders in children. Migraine is a primary central nervous system disorder characterized by triggered or spontaneous episodes of activation of trigemino-vascular complex, neurogenic inflammation around vessels and meninges, and stimulation of the peripheral and central pain pathways of the trigemino-cervical complex. The triptans, by their selective agonistic action on 5-HT1B/1D receptors, are very effective in the treatment of migraine pain and associated symptoms. Early studies on the safety and efficacy of triptans in the management of childhood migraine show encouraging results. We propose a stratified-care model for the management of migraine in children, and discuss pharmacotherapy based on the pathophysiologic mechanisms of migraine pain. Management of tension-type headaches requires comprehensive medical and psychologic evaluation and an individualized approach for a successful outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11898510     DOI: 10.1007/s11910-001-0010-1

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   6.030


  39 in total

1.  Intranasal sumatriptan for the acute treatment of migraine in children.

Authors:  M A Ueberall; D Wenzel
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

2.  Treatment of migraine attacks with sumatriptan.

Authors: 
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

Review 3.  How do the currently used prophylactic agents work in migraine?

Authors:  P J Goadsby
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

4.  Multicenter prospective evaluation of proposed pediatric migraine revisions to the IHS criteria. Pediatric Headache Committee of the American Association for the Study of Headache.

Authors:  P Winner; W Wasiewski; J Gladstein; S Linder
Journal:  Headache       Date:  1997-10       Impact factor: 5.887

Review 5.  The scientific basis of medication choice in symptomatic migraine treatment.

Authors:  P J Goadsby
Journal:  Can J Neurol Sci       Date:  1999-11       Impact factor: 2.104

Review 6.  Evidence based migraine prophylactic drug therapy.

Authors:  W J Becker
Journal:  Can J Neurol Sci       Date:  1999-11       Impact factor: 2.104

Review 7.  Burden of migraine: societal costs and therapeutic opportunities.

Authors:  R B Lipton; W F Stewart; M von Korff
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

8.  The efficacy of metoclopramide in the treatment of migraine headache.

Authors:  G L Ellis; J Delaney; D A DeHart; A Owens
Journal:  Ann Emerg Med       Date:  1993-02       Impact factor: 5.721

Review 9.  Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration.

Authors:  W F Stewart; A Shechter; R B Lipton
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

Review 10.  Migraine. Patterns of healthcare use.

Authors:  P E Stang; J T Osterhaus; D D Celentano
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

View more
  1 in total

1.  Benign paroxysmal vertigo of childhood: A review of the literature.

Authors:  Glenna Batson
Journal:  Paediatr Child Health       Date:  2004-01       Impact factor: 2.253

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.